Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Common Equity (2017 - 2025)

Cue Biopharma (CUE) has disclosed Common Equity for 9 consecutive years, with $26.4 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 51.05% to $26.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.4 million through Dec 2025, up 51.05% year-over-year, with the annual reading at $26.4 million for FY2025, 51.05% up from the prior year.
  • Common Equity hit $26.4 million in Q4 2025 for Cue Biopharma, up from $13.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $72.9 million in Q2 2021 to a low of $6.6 million in Q1 2025.
  • Historically, Common Equity has averaged $42.6 million across 5 years, with a median of $44.3 million in 2023.
  • Biggest five-year swings in Common Equity: soared 54.01% in 2021 and later crashed 78.09% in 2025.
  • Year by year, Common Equity stood at $65.5 million in 2021, then rose by 0.29% to $65.7 million in 2022, then crashed by 43.54% to $37.1 million in 2023, then tumbled by 52.81% to $17.5 million in 2024, then surged by 51.05% to $26.4 million in 2025.
  • Business Quant data shows Common Equity for CUE at $26.4 million in Q4 2025, $13.2 million in Q3 2025, and $18.2 million in Q2 2025.